Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-07-07
2000-08-08
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
061002747
ABSTRACT:
Stable pharmaceutical compositions containing 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cycloheptic[1,2-b ]pyridine("DCL") and a DCL protective amount of a pharmaceutically acceptable basic salt such as calcium dibasic phosphate and an amount of at least one disintegrant, preferably two disintegrates such as microcrystalline cellulose and starch sufficient to provide dissolution of at least about 80% by weight of the pharmaceutical composition in about 45 minutes and suitable for oral administration to treat allergic reactions in mammals such as man are disclosed.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3940485 (1976-02-01), Levinson et al.
patent: 4008796 (1977-02-01), Aylon
patent: 4282233 (1981-08-01), Vilani
patent: 4371516 (1983-02-01), Gregory et al.
patent: 4552899 (1985-11-01), Sunshine et al.
patent: 4659716 (1987-04-01), Villani et al.
patent: 4731447 (1988-03-01), Schumacher et al.
patent: 4777170 (1988-10-01), Heinrich
patent: 4783465 (1988-11-01), Sunshine et al.
patent: 4804666 (1989-02-01), Piwinski et al.
patent: 4863931 (1989-09-01), Schumacher et al.
patent: 4990535 (1991-02-01), Cho et al.
patent: 5019591 (1991-05-01), Gardner et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5100675 (1992-03-01), Cho et al.
patent: 5314697 (1994-05-01), Kwan et al.
patent: 5595997 (1997-01-01), Aberg et al.
patent: 5731319 (1998-03-01), Aberg et al.
patent: 5900421 (1999-05-01), Handley et al.
patent: 5939426 (1999-08-01), McCullough
Wood, et al., "Mechanisms of antimotion sickness drugs", Aviation, Space, and Environmental Medicine, Sep. 1987, A262-A265.
Wood, "Antimotion sickness and antiemetic drugs", Drugs, 1979, 17:471-479.
Wein, "Pharmacology of incontinence", Urologic Clinics of North America, Aug. 1995, 22(3):557-577.
Van Cauwenberge, "New data on the safety of Loratadine", Drug Invest., 1992, 4(4):283-291.
McCue, "Safety of antihistamines in the treatment of allergic rhinitis in elderly patients", Arch. Fam. Med., 1996, 5:464-468.
Roman, et al., "Loratadine-A review of recent finding in pharmacology phamacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine", Clin. Reviews in Allergy, 1993, 11:89-110.
Simons, "H1-receptor antagonists Comparative tolerability and safety", Drug Safety, 1994, 10(5):350-380.
Temple, et al., "Loratadine, an antihistamine, blocks antigen-and ionophore-induced leukotriene release from human lung in vitro", Prostaglandins, Apr. 1988, 35(4):549-554.
Sunahara, et al., "Pharmacological interventions for motion sickness: Cardiovascular Effects", Aviation, Space and Environmental Medicine, Sep. 1987, A270-A276.
Zhong, et al., "HPLC-Determination of Loratadine and its active metabolite descarboethoxyloratadine inhuman plasma", Pharmazie, 1994, 49(H. 10):736-739.
Yarker, et al., "Oxybutynin,. A review of its pharmacodynamic and phamacokinetic properties, and its therapeutic use in detrusor instability", Drugs and Aging, 1995, 6(3):243-262.
Parkinson, et al., "Evaluation of Loratadine as an inducer of liver microsomal cytochrome P450 in rats and mice", Biochemical Pharmacology, 1992, 43(10):2169-2180.
Van Peer, et al., "Ketoconazole inhibits loratadine metabolism in man", Beerse, Belgium, Abstract 1234, p. 34 (No publication date available).
Peggs, et al, "Antihistamines: The old and the new", American Family Physician, Aug. 1995,52(2):593-600.
Petrin, "Bewegungskrankheit und ihre therapie/Eine Ubersicht (Motion sickness and its treatment)", Schweiz, Rundschau Med., 1974, (PRAXIS) 63:79-81.
Quercia, et al., "Focus on Loratadine: A new second-generation nonsedating H1-receptor antagonist", Hosp. Formul., 1993, 28:137-153.
Resnick, "Urinary incontinence", The Lancet, 1995, 346:94-99.
Massad, et al., "The pharmacokinetics of intravesical and oral oxybutynin chloride", The J. of Urology, Aug. 1992, 148:595-597.
Miadonna, et al., "Inhibitory effect of the H1 antagonist loratadine on histamine release from human basophils", Int. Arch Allergy Immunol., 1994, 105:12-17.
Mirakhur, et al., "Glycopyrrolate: pharamacology and clinical use", Anaesthesia, 1983, 38:1195-1204.
Mitchelson, "Pharmacological agents affecting emesis: A review (Part II)", Drugs, 1992, 43(4):443-463.
Muskat, et al., "The use of scopolamine in the treatment of detrusor instability", The J. of Urology, 1996, 156:1989-1990.
Nelemans, Side Effects of Drugs Annual 12, Elsevier Science Publishers B.V., 1988, 144-147.
Kohl, et al., "New pharmacologic approaches to the prevention of space/motion sickness", J. Clin. Pharmacol., 1991, 31:934-946.
Kohl, et al., "Control of nausea and autonomic dysfunction with terfenadine, a peripherally acting antihistamine", Aviation, Space, and Environmental medicine, May 1991, 392-396.
Kubo, et al., "Antimuscarinic effects of antihistamines: Quantitative evaluation by receptor-binding assay", Japan. J. Pharmacol., 1987, 43:277-282.
Lathers, et al., "Pharmacology in space: Part 2. Controlling motion sickness", TiPS, Jun. 1989, 10:243-250.
Levin, et al., "Direct measurement of the anticholinergic activity of a series of pharmacological compounds on the canine and rabbit urinary bladder", The J. of Urology, Aug. 1982, 128:396-398.
Lunde, Side Effects of Drugs Annual 14, Elsevier Science Publishers B.V., 1990, 135-143.
Housley, et al., "Histamine and related substances influence neurotransmission in the semicircular canal", Hearing Research, 1988, 35:87-98.
Jankowski, et al., "Effect of terfenadine on nasal provocation", Int. Arch. Allergy Immunol., 1993, 101:311-317.
Kaliner, "Nonsedating antihistamines: Pharmacology, clinical efficacy and adverse effects", American Family Physician, Mar. 1992, 45(3):1337-1342.
Kleine-Tebbe, et al., "Inhibition of IgE-and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine", J. Allergy Clin. Immunol., 1994, 93:494-500.
Knowles, "Astemizole and terfenadine-induced cardiovascular effects", The Canadian J. of Hospital Pharmacy, Feb. 1992, 45(1):33-37.
Kohl, et al., "Lack of effects of astemizole on vestibular ocular reflex, motion sickness, and cognitive performance in man", Aviation, Space, and Environmental Medicine, Dec. 1987, 1171-1174.
Dorje, et al., "Antagonist binding profiles of five cloned human muscarinic receptor subtypes", The J. of Pharm. And Experimental Therapeutics, 1991, 256:727-733.
Lunde, Side Effects of Drugs Annual 12; A worldwide yearly survey of new data and trends, Elsevier Science Publishers B.V., 1988, 142-143.
Ebert, "Soft elastic gelatin capsules: a unique dosage form", Pharmaceutical Technology, 1977, 44-50.
Gengo, "Dilemma: Antihistamine selection: Use vs. Side effects", U.S. Pharmacist, Nov. 1990, 59-92.
Regula Herzog, et al., Annual Review of Gerontology and Geriatrics, 1989, 9:74-119.
Hilbert, et al., "Pharmacokinetics and dose proportionality of loratadine", J. Clin. Pharmacol. 1987, 27:694-698.
Brion, et al., "Evaluation of the antimuscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers", Br. J. clin. Pharmac. 1988, 25:27-32.
Carmeliet, "Voltage-and time-dependent block of the delayed K+current in cardiac myocytes by dofetilide", The J. of Pharm. And Experimental Therapeutics, 1992, 262(2):809-817.
Cheung, et al., "Investigation of anti-motion sickness drugs in the squirrel monkey", J. Clin. Pharmacol, 1992, 32:163-175.
Clissold, et al., "Loratadine a preliminary review of its pharmacodynamic properties and therapeutic efficacy", Drugs, 1989, 37:42-57.
Cooke, "Glycopyrrolate in bladder dysfunction", SA Medical Journal, 1983, 3.
Craft, "Torsade de pointes after astemizole overdose", Br. Medical Journal, 1986, 292:660.
Andersen, et al., "Adverse drug interactions clinically important for the dermatologist", Arch Dermatol, 1995, 131:468-473.
Barnett, et al., New Perspectives in Histamine Research, Birkhauser Verlag Basel, pp. 181-196 (1991).
Berge, et al., "Pharmaceutical salts"
Henley III Raymond
Hoffman Thomas D.
Schering Corporation
LandOfFree
8-chloro-6,11-dihydro-11- does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 8-chloro-6,11-dihydro-11- , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 8-chloro-6,11-dihydro-11- will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1150487